Effective antibiotic therapy depends critically on how drugs reach and persist in infected tissues. Clinical outcomes, resistance emergence, and dosing safety all follow from pharmacokinetic determinants of tissue penetration described by experts such as William A. Craig University of Wisconsin–Madison and Jason A. Roberts Monash University. Understanding these determinants helps clinicians choose agents and regimens that achieve therapeutic exposure at the infection site.
Physiochemical and systemic determinants
At the molecule level, molecular size and lipophilicity govern passive diffusion across endothelial barriers. Small, lipophilic drugs cross cell membranes more readily, while large or highly polar molecules are restricted to vascular and interstitial compartments. Ionization determined by drug pKa and local pH alters membrane permeability and trapping phenomena, making acidic environments like abscesses hostile to basic drugs and vice versa. Plasma protein binding reduces the free fraction available to penetrate tissue; only unbound drug equilibrates with the interstitium. Systemic factors such as blood flow and capillary permeability set the delivery rate to tissues, so poorly perfused regions such as diabetic foot ulcers or necrotic centers of tuberculous lesions receive lower exposures. These interactions are variable across individuals and disease states.
Transporters, inflammation, and clinical consequences
Active uptake and efflux transporters at tissue barriers, including the blood–brain barrier, limit or enhance accumulation. Inflammation can transiently increase capillary permeability and transporter expression, modifying penetration into the cerebrospinal fluid or infected lungs. Volume of distribution and systemic clearance determine how much drug remains available over time to move into tissues, shaping dosing frequency and infusion strategies. Jason A. Roberts Monash University emphasizes applying pharmacokinetic/pharmacodynamic targets to compensate for limited penetration using higher doses, extended infusions, or drugs with favorable tissue distribution.
Poor tissue penetration leads to treatment failure and selection of resistant subpopulations when pathogens are exposed to subtherapeutic concentrations. In territories with high burdens of infections such as tuberculosis, lesion-specific penetration is central to cure and relapse risk, and cultural or resource constraints may limit access to optimized formulations. Environmental consequences include community-level amplification of resistance when inadequate dosing results in persistent shedding. Clinicians should therefore integrate knowledge of physicochemical properties, patient physiology, and local epidemiology to select antibiotics that achieve effective tissue concentrations while minimizing toxicity. Tailoring therapy based on these pharmacokinetic principles improves both individual outcomes and public health.